GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B4876 K-Ras(G12C) inhibitor 12Summary: allosteric inhibitor of K-Ras(G12C)
- A8886 UNBS 5162Summary: A pan-antagonist of CXCL chemokines
- A4233 MethylprednisoloneTarget: Glucocorticoid ReceptorsSummary: Apoptosis inducer,GR agonist
- A3125 5-IodotubercidinTarget: Adenosine KinasesSummary: Adenosine kinase inhibitor,potent
- A3147 AH 6809Summary: EP and DP receptor antagonist
- A3159 Alosetron HydrochlorideSummary: 5-HT3 receptor antagonist,potent and highly selective
- A3166 AM0953 CitationSummary: Potent LPA1 receptor antagonist
- A3167 AM-095 free baseTarget: LPA ReceptorsSummary: Potent LPA1 receptor antagonist
- A3168 AM630Summary: CB2 receptor antagonist,selective and competitive
- A3170 AM9662 CitationTarget: LPA ReceptorsSummary: LPA1 antagonist, oral active, high affinity, selective,